Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Разработка и оценка программы кардиореабилитации только для женщин (CARE) (CARE)

6 ноября 2026 г. обновлено: Melvyn Rubenfire, University of Michigan

Разработка и оценка программы кардиореабилитации только для женщин

The purpose of this randomized controlled study is to investigate the effect(s) of a pilot women-only cardiac rehabilitation (CR) program. The study team will be testing the effectiveness, compliance and enjoyment of this women's only cardiac rehabilitation (CR) program by comparing outcomes to those randomized to receive Michigan Medicine's current CR program (standard care), which includes people of all genders.

Study hypotheses:

  • Women randomized to women-specific CR programming will have superior attendance and completion rates compared to women attending mixed-sex CR programming.
  • Women randomized to women-specific CR programming will experience greater improvement in clinical outcomes in comparison to those in mixed-sex CR programming.

Обзор исследования

Подробное описание

This registration was updated on 11/24/2025 due to amendments that were approved at the IRBMED.

Тип исследования

Интервенционный

Регистрация (Оцененный)

60

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Beth Perrotta
  • Номер телефона: 734-232-6865
  • Электронная почта: eperrott@umich.edu

Места учебы

    • Michigan
      • Ann Arbor, Michigan, Соединенные Штаты, 48109
        • Рекрутинг
        • University of Michigan
        • Контакт:
          • Beth Perotta
          • Номер телефона: 734-232-6865
          • Электронная почта: eperrott@umich.edu
        • Главный следователь:
          • Melvyn Rubenfire, MD

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 40 лет до 80 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Женский

Описание

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability to participate in study procedures for the duration of the study
  • Identify as a female
  • Be between the ages of 40-80 years, inclusive
  • Documented diagnosis of CR indications of stable and/or refractory angina pectoris (with or without coronary obstructive disease), acute myocardial infarction (MI) within the preceding 12 months (including MINOCA), percutaneous coronary interventions (PCI), surgical and transvalvular aortic valve replacement, spontaneous coronary artery dissection (SCAD), post-aortic surgery with or without aortic valve, coronary artery bypass grafting (CABG) and mitral valve replacement or repair with or without CABG
  • Referred to outpatient CR at the University of Michigan, Domino's Farms or Brighton Center for Specialty Care Cardiac Rehabilitation site based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedure.

Exclusion Criteria:

  • Not being "cleared" for CR based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedures
  • Prior participation in CR
  • Inability to understand spoken and written English, either due to language barrier or cognitive limitation for any reason, including deaf or blind
  • Frailty, fall risk, or muscle, joint or back pain as defined as the inability to perform activities of daily living without limitations and engage in mild physical activity (i.e. unable to walk up 1 flight of stairs unaided)
  • Any of the following as the indication for CR: aortic repair or replacement for aortic dissection, untreated or greater than New York Heart Association (NYHA) class II congestive heart failure, cardiac transplant candidate or recipient, tricuspid or pulmonic valve repair or replacement
  • Life threatening ventricular arrythmias without an implanted defibrillator; very frequent premature ventricular contraction or premature atrial contractions symptomatic or not; poorly controlled atrial fibrillation
  • Associated more than mild valvular heart disease, untreated congestive heart failure; unstable angina or heart pain with minimal activity; angina or congestive heart failure limiting ability to climb one flight of stairs without help (NHYA Functional Classification >2)
  • Severe pulmonary hypertension (right heart systolic pressure greater than 60 millimeters of mercury); clot in the heart; treated venous thrombosis with or without pulmonary embolism in past 6 months; more than mild dyspnea related to chronic lung disease or asthma
  • Chronic kidney disease (creatinine >2 milligrams per deciliter (mg/dl)); symptomatic active liver disease (infectious or inflammatory), symptomatic chronic liver disease (except for nonalcoholic fatty liver disease), kidney dialysis or kidney transplant recipient, active or chronic renal disease (rise by 0.5mg/dL in past 3 months or chronic elevated serum creatinine 2.0 milligrams per milliliter (mg/mL) or greater.
  • Poorly controlled diabetes defined as uninterrupted HbA1c >8.0% for ≥1 year despite standard care, baseline HbA1c prior to CR > 8.5%.
  • Immunosuppressive drug requirement, acute anemia, chronic anemia with Hemoglobin < 10mg/mL
  • Limiting chronic muscle, joint, or back pain; identified as fall risk from poor balance or neurologic syndromes; frailty defined as the inability to perform activities of daily living in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality
  • Untreated or active substance abuse/addiction including alcohol and drugs; depression (defined as a score ≥ 15 or depression positive answer to #8 or #9 on Patient Health Questionnaire-9) unless deemed acceptable by mental health care provider; severe anxiety
  • Severe obesity (Body mass index ≥ 40 kilograms/meters squared), history of bariatric surgery within previous 3 years and >5% body weight loss over preceding 12 months; chronic venous insufficiency with cellulitis or > 1+ edema unless controlled with support hose.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Одинокий

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Программа кардиореабилитации только для женщин

This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.

Women-specific education content will be provided monthly in addition to the standard weekly "mini-teaches." This education content will be developed and delivered by experience health care professionals that are experts in women's health.

Активный компаратор: Программа реабилитации Standard of Care (смешанный пол)

This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Cardiac Rehabilitation (CR) attendance rate
Временное ограничение: 12 weeks (post CR)

CR completion rate defined as number of patients that "graduated" or completed CR programming versus the number of patients that started CR programming [i.e. attended 75% or more of the prescribed sessions (≥27 out of 36)], expressed as a percentage of participants per arm.

12 weeks (post CR)
Cardiac Rehabilitation (CR) attendance rate - percentage
Временное ограничение: 12 weeks (post CR)

Number of CR sessions attended out of number of CR sessions prescribed, expressed as a percentage

12 weeks (post CR)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Optimal blood pressure (BP) control
Временное ограничение: 12 weeks (post CR)

Percentage of patients that have optimal BP control at program discharge, defined as systolic blood pressure (SBP) less than 130 mmHg and diastolic blood pressure (DBP) less than 80 Millimeters of mercury (mmHg).

12 weeks (post CR)
Change in resting systolic blood pressure (SBP)
Временное ограничение: Baseline, 12 weeks (post CR)

Change in resting SBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg.

Baseline, 12 weeks (post CR)
Change in resting diastolic blood pressure (DBP)
Временное ограничение: Baseline, 12 weeks (post CR)

Change in resting DBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg.

Baseline, 12 weeks (post CR)
Improvement in depression based on the Patient Health Questionnaire (PHQ)-9
Временное ограничение: Baseline to 12 weeks (post CR)

Percentage (%) of patients with a positive depressive screen at CR entrance that experience a decrease in depressive symptoms (reduction in one or more levels of severity) as measured by changes in the Patient Health Questionnaire (PHQ)-9 score from baseline to completion of CR.

The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression.

Baseline to 12 weeks (post CR)
Change in Patient Health Questionnaire (PHQ)-9 score
Временное ограничение: Baseline to 12 weeks (post CR)

A change in PHQ-9 scores will be measured during the first 12 weeks of the study. The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression.

Baseline to 12 weeks (post CR)
Change in Patient Health Questionnaire (PHQ)-9 score
Временное ограничение: 12 weeks (post CR), 24 weeks

The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression. A change in PHQ-9 scores will be measured during the first 12 weeks of the study and will be repeated 12 weeks following program completion.

12 weeks (post CR), 24 weeks
Improvement in functional capacity measured by the six-minute walk test
Временное ограничение: Baseline, up to 12 weeks (post CR)

Percentage of patients that achieve an increase in distance walked, in meters, by at least 10%, after participation in CR as measured by the 6-minute walk test (6MWT).

Baseline, up to 12 weeks (post CR)
Change in 6-minute walk test distance
Временное ограничение: Baseline, 12 weeks (post CR)

The distance walked in six minutes on a standard course will be measured in meters at baseline and CR Exit

Baseline, 12 weeks (post CR)
Improvement in functional capacity Metabolic Equivalents (METs)
Временное ограничение: Baseline, 12 weeks (post CR)

Percentage of patients that display an overall mean increase in estimated METs (0.93 METs, 12.4%): with greatest increase occurring in "low" fitness patients < 5 METs (1.3 METs, 35% increase), followed by "moderate" fitness 5-8 METs (1.03 METs, 16% increase), and "high" fitness > 8 METs (0.77 METs, 8% increase)2,3 after participation in CR as measured by estimated exercise session peak METs.

Baseline, 12 weeks (post CR)
Change in estimated exercise session peak METs
Временное ограничение: Baseline, up to 12 weeks (post CR)

The difference in estimated peak METs between baseline (defined as the third session to account for learning effect) and program completion.

Baseline, up to 12 weeks (post CR)

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Соавторы

Следователи

  • Главный следователь: Melvyn Rubenfire, MD, University of Michigan

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

5 мая 2025 г.

Первичное завершение (Оцененный)

1 августа 2027 г.

Завершение исследования (Оцененный)

1 августа 2027 г.

Даты регистрации исследования

Первый отправленный

16 января 2025 г.

Впервые представлено, что соответствует критериям контроля качества

16 января 2025 г.

Первый опубликованный (Действительный)

20 января 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

12 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

6 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться